ABVX:EPA
Abivax SA
79,55 €
0,00%
(0,00) 1D
4 nën, 5:38:16 m.d., GMT+1 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për ABVX...
Kapitalizimi i tregut
7,28 mld
Vëllimi mesatar
111,13 mijë
Vëllimi
0,00
Maksimumi 52-javor
139,00 €
Minimumi 52-javor
60,45 €
Fitimet për aksion
-5,20 €
Aksionet në qarkullim
87,55 mln
Numri i punonjësve
98
Kapitalizimi i tregut
7,28 mld
Vëllimi mesatar
111,13 mijë
Vëllimi
0,00
Maksimumi 52-javor
139,00 €
Minimumi 52-javor
60,45 €
Fitimet për aksion
-5,20 €
Aksionet në qarkullim
87,55 mln
Numri i punonjësve
98
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
JHNewsAndGuide.com
·
1 orë më parë
Stocks surge, and the Dow soars 1,500 points as oil prices tumble following the US midterm elections
Investing.com
·
1 orë më parë
US Midterm Fallout: What Does the ’Blue Tsunami’ Mean for the S&P 500?
TradingView
·
1 orë më parë
DJI: Dow Jones Jumps 3% in Stunning Post-Election Turnaround, AI Stocks Miss Out
Yahoo Finance
·
5 orë më parë
Dow, S&P 500, Nasdaq Futures Mixed After A Democratic Sweep In Midterms: NVDA, MU, SNDK, NBIS, IREN In Focus
Profili
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Rreth Abivax SA
Drejtori ekzekutivMarc de Garidel | Hartmut J. Ehrlich
Punonjësit98
Themeluar më4 dhj 2013
Selia-
Sektori-
Industry-
Uebsajtiabivax.com